Literature DB >> 9844766

Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever.

S Kiraz1, I Ertenli, M Arici, M Calgüneri, I Haznedaroglu, I Celik, S Pay, S Kirazli.   

Abstract

OBJECTIVE: To evaluate whether basal levels of circulating cytokines and selectins exhibit a distinct profile in attack-free, non-colchicine taking familial Mediterranean fever (FMF) patients compared to normal healthy controls, and to determine the effect of colchicine treatment on these parameters.
METHODS: Serum levels of interleukin (IL)-6, IL-8, tumor necrosis factor (TNF)-alpha, and soluble P-, E-, and L-selectin in attack-free, asymptomatic, non-colchicine using FMF patients (n = 11) and in normal controls (n = 10) were studied. Following 2 months of colchicine treatment the same parameters were evaluated again in the FMF patients.
RESULTS: Before colchicine treatment the serum levels of all parameters except soluble P-selectin were significantly higher in FMF patients than in controls. After two months of treatment statistically significant decreases were observed in these parameters (p < 0.05).
CONCLUSION: A distinct profile of IL-6, IL-8, TNF-alpha, and soluble E- and L-selectin levels was observed in FMF patients, which could reflect the presence of sustained inflammation in attack-free FMF patients. The effect of colchicine on these parameters suggests its therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9844766

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  23 in total

1.  Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout.

Authors:  Daria B Crittenden; R Aaron Lehmann; Laura Schneck; Robert T Keenan; Binita Shah; Jeffrey D Greenberg; Bruce N Cronstein; Steven P Sedlis; Michael H Pillinger
Journal:  J Rheumatol       Date:  2012-06-01       Impact factor: 4.666

2.  Colchicine to decrease NLRP3-activated inflammation and improve obesity-related metabolic dysregulation.

Authors:  Andrew P Demidowich; Angela I Davis; Nicket Dedhia; Jack A Yanovski
Journal:  Med Hypotheses       Date:  2016-04-25       Impact factor: 1.538

3.  Evaluation of endothelial dysfunction in patients with familial Mediterranean fever: the relationship between the levels of asymmetric dimethylarginine and endocan with carotid intima-media thickness and endothelium-dependent vasodilation.

Authors:  Veysel Ozalper; Muammer Kara; Alpaslan Tanoglu; Ibrahim Cetındaglı; Coskun Ozturker; Yusuf Hancerlı; Serdar Hıra; Kemal Kara; Yavuz Beyazıt; Yusuf Yazgan
Journal:  Clin Rheumatol       Date:  2017-01-10       Impact factor: 2.980

4.  Cardiac autonomic functions in children with familial Mediterranean fever.

Authors:  Murat Şahin; Mustafa Kır; Balahan Makay; Pembe Keskinoğlu; Elçin Bora; Erbil Ünsal; Nurettin Ünal
Journal:  Clin Rheumatol       Date:  2014-06-15       Impact factor: 2.980

Review 5.  Tofacitinib for the treatment for colchicine-resistant familial Mediterranean fever: case-based review.

Authors:  Hazan Karadeniz; Aslıhan Avanoğlu Güler; Nuh Atas; Hasan Satış; Reyhan Bilici Salman; Hakan Babaoglu; Abdurrahman Tufan
Journal:  Rheumatol Int       Date:  2019-12-07       Impact factor: 2.631

6.  Continuity of cytokine activation in patients with familial Mediterranean fever.

Authors:  Sait Bagci; Bulent Toy; Ahmet Tuzun; Yuksel Ates; Murat Aslan; Ali Inal; Mustafa Gulsen; Necmettin Karaeren; Kemal Dagalp
Journal:  Clin Rheumatol       Date:  2004-05-01       Impact factor: 2.980

7.  The Relationship Among the Level of Serum Amyloid A, High-Density Lipoprotein and Microalbuminuria in Patients With Familial Mediterranean Fever.

Authors:  Ali Ugur Uslu; Bahattin Aydin; Ibrahim Serhat Icagasıoğlu; Sevket Balta; Köksal Deveci; Filiz Alkan; Gürsel Yıldız; Ali Sahin
Journal:  J Clin Lab Anal       Date:  2016-04-19       Impact factor: 2.352

8.  Urinary glycosaminoglycans in the course of familial Mediterranean fever.

Authors:  Esra Baskin; Umit Saatçi; Gönenç Ciliv; Aysin Bakkaloglu; Nesrin Besbas; Rezan Topaloglu; Seza Ozen
Journal:  Eur J Pediatr       Date:  2003-03-04       Impact factor: 3.183

Review 9.  Cardiac disease in familial Mediterranean fever.

Authors:  Eren Erken; Ertugrul Erken
Journal:  Rheumatol Int       Date:  2017-10-20       Impact factor: 2.631

Review 10.  Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy.

Authors:  Jae J Chae; Ivona Aksentijevich; Daniel L Kastner
Journal:  Br J Haematol       Date:  2009-05-14       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.